Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 67Other hematologic neoplasm 10Lymphoid 10Gastrointestinal 2Tumor-Agnostic 1Thoracic 1Other 1Genitourinary 1

Conditions

Purpura 1Nausea 1Macroglossia 1Lymphadenopathy 1Immunoglobulin Light-chain Amyloidosis 1Hepatomegaly 1Gastrointestinal Hemorrhage 1Diarrhea 1Constipation 1

Interventions

Exercise 27Metformin 24Methods 14Radiotherapy 13Early Intervention, Educational 13Educational Status 12Counseling 12Surveys and Questionnaires 10Standard of Care 10Nutrition Assessment 9Resistance Training 8Diet Therapy 8Cisplatin 8naloxegol 7Tirzepatide 7Diet 7alvimopan 6Psychiatric Rehabilitation 6Fibroblast Growth Factor 7 6Caloric Restriction 6Radiation 5Low-Level Light Therapy 5Liraglutide 5Injections 5Exenatide 5Dexamethasone 5Cryotherapy 5semaglutide 4angiotensin I (1-7) 4Vitamin D 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × isatuximab × Other × Clear all
NCT03499808 2025-09-09

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

SWOG Cancer Research Network

Phase 2 Completed
43 enrolled 23 charts
GastrointestinalOtherPlasma cell

Lymphadenopathy, Immunoglobulin Light-chain Amyloidosis, Constipation, Diarrhea, Gastrointestinal Hemorrhage, Hepatomegaly, Macroglossia, Nausea, Purpura

Data powered by HemOnc (CC BY 4.0) Colophon âš¡